Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
24.17
-0.44 (-1.79%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Stoke Therapeutics Employees
Stoke Therapeutics had 170 employees as of December 31, 2025. The number of employees increased by 42 or 32.81% compared to the previous year. That makes Stoke Therapeutics the 27,977th largest employer in the world and 3,538th in the United States.
Employees
170
Change (1Y)
42
Growth (1Y)
32.81%
Revenue / Employee
$162,282
Profits / Employee
-$1,222,959
Market Cap
1.56B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 170 | 42 | 32.81% |
| Dec 31, 2024 | 128 | 18 | 16.36% |
| Dec 31, 2023 | 110 | -7 | -5.98% |
| Dec 31, 2022 | 117 | 15 | 14.71% |
| Dec 31, 2021 | 102 | 23 | 29.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 305 |
| Structure Therapeutics | 281 |
| uniQure | 221 |
| Zenas BioPharma | 167 |
| Innoviva | 159 |
STOK News
- 1 day ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 6 days ago - Stoke Therapeutics announces presentations of data for STK-002 - TheFly
- 6 days ago - Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Business Wire
- 12 days ago - Stoke Therapeutics announces two presentations of data for STK-002 at AAO - TheFly
- 12 days ago - Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Business Wire
- 13 days ago - Stoke completes meeting with FDA to align aspects with NDA for zorevunersen - TheFly
- 13 days ago - Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - Business Wire
- 24 days ago - Stoke Therapeutics names Bo Cumbo to board of directors - TheFly